International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Apr 2011
Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity.
To evaluate pharmacological properties of H6CAHA, an adamantyl-hydroxamate histone deacetylase inhibitor, and to investigate its effect on prostate cancer cells following exposure to γ-radiation in vitro and in vivo. ⋯ These results support the potential therapeutic value of H6CAHA in combination with radiation and support the rationale for further clinical investigation.
-
Int. J. Radiat. Oncol. Biol. Phys. · Mar 2011
ReviewRadiotherapy in small-cell lung cancer: lessons learned and future directions.
Although chemotherapy is an essential component in the treatment of small-cell lung cancer, improvements in survival in the past two decades have been mainly achieved by the appropriate application of radiotherapy. The aim of the present study was to review the key developments in thoracic radiotherapy and prophylactic cranial radiotherapy and to discuss the rationale behind key ongoing studies in small-cell lung cancer.
-
Int. J. Radiat. Oncol. Biol. Phys. · Mar 2011
Randomized Controlled Trial Comparative StudyAcute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer.
To compare the toxicity between hypofractionation vs. conventional fractionation schedules in patients with high-risk prostate cancer. ⋯ Our findings suggest that the hypofractionation regimen used in our study is safe, with only a slight, nonsignificant increase in tolerable and temporary acute toxicity compared with the conventional fractionation schedule. The severity and frequency of late complications was equivalent between the two treatment groups.